In conclusion, the present systematic review provides updated pooled risk estimates for the association of CYP2C19 LOF allele status with efficacy and safety of clopidogrel-based antiplatelet therapy in non-East Asian patients with stroke or TIA, including Europeans. This evidence concerns the gene CYP2C19 and stroke disorder.